In another phase IIa trial, UCPVax, a vaccine composed of two CD4w helper peptides derived from TERT (NCT04280848, https://www.clinicaltrials.gov/study/NCT04280848, accessed on 27 October 2024), was evaluated in 31 glioblastoma, IDH-wildtype, MGMT-unmethylated patients and proved to be highly immunogenic with a relatively safe profile, providing an improved OS rate in this population, which presents a rationale for further clinical studies of UCPVax in glioblastoma patients, possibly in combination with other therapies [106]. Here, MGMT is linked to glioblastoma.